

Resource Summary Report

Generated by [RRID](#) on Aug 14, 2026

Phospho-Akt (Ser473) (D9E) XP(tm) Rabbit mAb (Biotinylated)

RRID:AB_2224726

Type: Antibody

Proper Citation

Cell Signaling Technology Cat# 5012, RRID:AB_2224726

Antibody Information

URL: http://antibodyregistry.org/AB_2224726

Proper Citation: Cell Signaling Technology Cat# 5012, RRID:AB_2224726

Target Antigen: AKT1

Host Organism: rabbit

Clonality: monoclonal

Comments: Applications: W. Consolidation on 10/2018: AB_10694690, AB_2224726.

Antibody Name: Phospho-Akt (Ser473) (D9E) XP(tm) Rabbit mAb (Biotinylated)

Description: This monoclonal targets AKT1

Target Organism: rat, cow, mouse, human

Antibody ID: AB_2224726

Vendor: Cell Signaling Technology

Catalog Number: 5012

Record Creation Time: 20250820T022440+0000

Record Last Update: 20250820T133103+0000

Ratings and Alerts

No rating or validation information has been found for Phospho-Akt (Ser473) (D9E) XP(tm) Rabbit mAb (Biotinylated).

No alerts have been found for Phospho-Akt (Ser473) (D9E) XP(tm) Rabbit mAb (Biotinylated).

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 15 mentions in open access literature.

Listed below are recent publications. The full list is available at [RRID](#) .

Devlin KL, et al. (2025) Growth factors maintain intratumoral heterogeneity and drive therapeutic resistance in triple-negative breast cancer. *Cell reports*, 45(1), 116826.

Lin NH, et al. (2023) Neuroprotective Effects of a Multi-Herbal Extract on Axonal and Synaptic Disruption in Vitro and Cognitive Impairment in Vivo. *Journal of Alzheimer's disease reports*, 7(1), 51.

Kuriyama S, et al. (2022) Pigment Epithelium Derived Factor Is Involved in the Late Phase of Osteosarcoma Metastasis by Increasing Extravasation and Cell-Cell Adhesion. *Frontiers in oncology*, 12, 818182.

Hu SH, et al. (2022) Methylene-bridge tryptophan fatty acylation regulates PI3K-AKT signaling and glucose uptake. *Cell reports*, 38(11), 110509.

da Silva-Oliveira RJ, et al. (2022) Efficacy of Combined Use of Everolimus and Second-Generation Pan-EGFR Inhibitors in KRAS Mutant Non-Small Cell Lung Cancer Cell Lines. *International journal of molecular sciences*, 23(14).

Ramesh P, et al. (2022) BCL-XL inhibition induces an FGFR4-mediated rescue response in colorectal cancer. *Cell reports*, 38(7), 110374.

Tang G, et al. (2022) Butyrate ameliorates skeletal muscle atrophy in diabetic nephropathy by enhancing gut barrier function and FFA2-mediated PI3K/Akt/mTOR signals. *British journal of pharmacology*, 179(1), 159.

Tognetti M, et al. (2021) Deciphering the signaling network of breast cancer improves drug sensitivity prediction. *Cell systems*, 12(5), 401.

Lin NH, et al. (2021) Elevated GFAP isoform expression promotes protein aggregation and compromises astrocyte function. *FASEB journal : official publication of the Federation of American Societies for Experimental Biology*, 35(5), e21614.

Perino S, et al. (2020) Novel Miniaturized Drug Conjugate Leverages HSP90-driven Tumor Accumulation to Overcome PI3K Inhibitor Delivery Challenges to Solid Tumors. *Molecular cancer therapeutics*, 19(8), 1613.

Paez DT, et al. (2019) Adenosine A1 receptors and mitochondria: targets of remote ischemic preconditioning. *American journal of physiology. Heart and circulatory*

physiology, 316(3), H743.

Costa R, et al. (2019) Impaired Mitochondrial ATP Production Downregulates Wnt Signaling via ER Stress Induction. *Cell reports*, 28(8), 1949.

Lun XK, et al. (2019) Analysis of the Human Kinome and Phosphatome by Mass Cytometry Reveals Overexpression-Induced Effects on Cancer-Related Signaling. *Molecular cell*, 74(5), 1086.

Watson SS, et al. (2018) Microenvironment-Mediated Mechanisms of Resistance to HER2 Inhibitors Differ between HER2+ Breast Cancer Subtypes. *Cell systems*, 6(3), 329.

Senagolage MD, et al. (2018) Loss of Transcriptional Repression by BCL6 Confers Insulin Sensitivity in the Setting of Obesity. *Cell reports*, 25(12), 3283.